TRTL-729 PK and Safety Study in Healthy Adults

Phase 1, open-label, single-arm trial of TRTL-729, sponsored by Tortugas Neuroscience. Primary endpoints: Number of Participants With Treatment-Emergent Adverse events (TEAEs) and Serious Adverse Events (SAEs) at Day 10, Number of Participants With Clinically Significant Change From Baseline in Vital Signs, Clinical Laboratory Values, and Electrocardiograms (ECGs) at Day 10 and 1 more. Started Sep 2026; status: recruiting.